NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Protego Biopharma

Protego Biopharma

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://www.protegobio.com

Last Round

Series B

Dec 1, 2025

Total Funding Raised

$181M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Protego Biopharma is a biotechnology company that develops a small molecule therapeutics platform aimed at reprogramming protein folding to treat systemic amyloid diseases and other protein misfolding disorders.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

small molecule therapeuticsprotein misfolding diseasepharmacological chaperonesdrug discovery platformUnfolded Protein ResponseUPRproteopathyUPR modulatorsprotein stabilizationdrug licensingpharma partnershipsprotein homeostasispreclinical biotechamyloidosis treatmentchemical chaperones

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Protego Biopharma Comps

Public and private peers based on sector, stage, and business model.

Protego Biopharma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Protego Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 1, 2025
Series ANov 17, 2021

Key People

Founding team and executive leadership

Brent Warner

Chief Executive Officer, Board Member

Executive Team

Protego Biopharma Investors

Notable investors and investment history

Protego Biopharma investors
InvestorRounds
MPM CapitalSeed, Series A
Omega FundsSeries B
ForbionSeries B
Digitalis VenturesSeries B
Vida VenturesSeries B, Series A
MPM BioImpactSeries B
Droia VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 27, 2026

    Open roles increased to 12, representing 50% of headcount.

  • Mar 3, 2026

    John M. Maraganore appointed to the Board of Directors.

Protego Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Protego Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Protego Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range26
Year Founded2011
Last FundingDec 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.